Safety and Performance of the ThecaFlex DRx™ System Port and Catheter for Chronic Intrathecal Access, Cerebrospinal Fluid (CSF) Aspiration, and DElivery of Nusinersen in Spinal Muscular Atrophy (SMA) Patients Resistant to Lumbar PunctuRE Trial (PIERRE)
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 90
- 试验地点
- 35
- 主要终点
- The proportion of subjects with successful Implantation of the ThecaFlex DRx™ Port and Catheter
研究概览
简要总结
The primary objective of the clinical investigation is to demonstrate successful clinical use of the ThecaFlex DRx™ System in delivering nusinersen in subjects with spinal muscular atrophy (SMA).
All enrolled subjects will undergo implantation of the investigational device (ThecaFlex DRx™ System) and will be followed for 12 months after receiving the implant. The 12-month data will be used to assess the primary endpoint support a Pre-Market Approval (PMA) application.
详细描述
This is a multicenter, multi-national, prospective, non-randomized, single arm, group sequential design, pivotal clinical investigation (device exemption study) to assess the safety and performance of the ThecaFlex DRx™ System in subjects with SMA.
The subject population will include subjects aged ≥ 3 years with SMA who are considered candidates for intrathecal port and catheter implantation because they require chronic, bolus intrathecal administration of necessary therapy, and who meet all the inclusion/exclusion criteria for the clinical investigation.
After a screening period of up to 200 days, all enrolled subjects will undergo implantation of the investigational device (ThecaFlex DRx™ System) and will be followed for 12 months after receiving the implant.
In agreement with the nusinersen dosing information, the treatment frequency will be adapted for non-naïve and naïve subjects:
Subjects who are not naïve to nusinersen should have nusinersen maintenance doses administered via the implant every 4 months (i.e., 4, 8, and 12 months after their last nusinersen dose, before enrollment in the clinical investigation).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 3 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is 3 years or older
- •Subject is diagnosed with SMA and is a candidate for Spinraza treatment as indicated in country-specific label
- •Subject resistant to lumbar puncture (LP), where resistance is defined as:
- •Subject with respiratory issues or other comorbidities who is at an increased risk for complications due to the need for repeat anesthesia and imaging radiation exposure to safely perform LP; or
- •Subjects for whom the treating physician determines implantation of the ThecaFlex DRx™ System is otherwise in the subject's best interest
- •Subject has been prescribed nusinersen via chronic intrathecal bolus administration in accordance with the country-specific drug labeling
- •Subject, per Investigator discretion, is able to undergo a percutaneous or open surgical procedure for index port and catheter implantation where at least 7 cm of the ThecaFlex DRx system catheter will be placed intrathecally
- •Subject (or subject's legally authorized representative) is willing and able to provide written informed consent; and
- •Subject and parent/caregiver able and willing to complete all clinical investigation procedures, measurements, and visits.
排除标准
- •Subject meets any of the contraindications for use of the ThecaFlex DRx System as outlined in the ThecaFlex DRx System Instructions for Use
- •Presence or history of (< 6 months prior to the procedure): an implanted microinfusion pump, intrathecal catheter, or other intrathecal drug delivery devices/component, or implanted shunt for drainage of cerebrospinal fluid (CSF), or reservoir in the CSF space (note: any ThecaFlex Port and Catheter System must not be placed in the same location as a previous indwelling port and catheter)
- •Subject is pregnant or nursing or plans to become pregnant during the course of the clinical investigation, or is a woman of childbearing potential or a man of reproductive age who is unwilling or unable to practice contraception, as described in Section 14.
- •Any condition or event, which in the opinion of the Investigator may adversely affect the safety and effective implantation and use of the ThecaFlex DRx system or confound the clinical investigation, including:
- •Severe structural impediment that may preclude safe implantation of the catheter and port
- •Major medical events (as defined per investigator's discretion) within 60 days prior to screening; or
- •Relevant surgeries (e.g., head and neck, back, etc.) within 60 days prior to screening or planned during the duration of the clinical investigation
- •Space-occupying lesion with mass effect
- •Posterior fossa mass
- •Arnold-Chiari malformation
- •Coagulation abnormalities and/or thrombocytopenia
- •Insufficient or inadequate skin or underlying fat to adequately protect the port or enough surface area to allow the skin to close safely
- •Subject is contraindicated for administration of nusinersen per its approved country-specific labeling
- •History of intrathecal granuloma formation
- •History of bacterial meningitis or aseptic meningitis within 6 months of screening
- •History of tumors or other spinal abnormalities documented by magnetic resonance imaging (MRI) or computed tomography (CT) that would interfere with the catheter implantation procedures or CSF circulation
- •History of hydrocephalus
- •Diagnosed degenerative muscular disease other than SMA
- •History of depression, cognitive impairment, or another psycho-behavioral problem that in the opinion of the Investigator may preclude safe participation in the clinical investigation and
- •Serious medical condition that, in the opinion of the investigator, may lead to reduced life expectancy beyond 12 months.
- •Subject is involved in another Investigation Device Exemption Study.
- •Subject has clinically meaningful immunosuppression, in the opinion of the investigator, either from therapy or a comorbid condition, which, in the opinion of the investigator, makes them a poor surgical candidate due to increased risk of infection.
研究组 & 干预措施
ThecaFlex DRx Port and Catheter System
Subjects who meet all of the inclusion and none of the exclusion would be eligible to receive the ThecaFlex DRx Port and Catheter System.
干预措施: ThecaFlex DRx System (Device)
结局指标
主要结局
The proportion of subjects with successful Implantation of the ThecaFlex DRx™ Port and Catheter
时间窗: 12 Months
The primary outcome measures the proportion of subjects with successful implantation of the ThecaFlex DRx™ Port and Catheter System who are able to receive successful intrathecal therapy infusion(s).
The proportion of subjects with successful Intrathecal Therapy Infusion(s) through 12 months
时间窗: 12 Months
次要结局
- Incidence of procedural complications through 12 months(12 months)
- Incidence of nusinersen-related AEs(12 months)
- Mean duration of radiation exposure from implant through 12-month follow-up(12 months)
- Proportion of subjects with reduced anesthesia and radiation exposure compared to repeat LP for nusinersen infusion in SMA subjects.(12 months)
- Incidence of device-related adverse events (AEs)/complications through 12 months(12 months)